Venclexta

Approved Uses

Venclexta is used to treat adults with certain types of blood and bone marrow cancers. It is approved for the treatment of:

• Chronic Lymphocytic Leukemia (CLL): A slow-growing cancer of the white blood cells.
• Small Lymphocytic Lymphoma (SLL): A type of cancer that primarily affects the lymph nodes.

Venclexta is also used to treat Acute Myeloid Leukemia (AML), a fast-growing cancer of the blood and bone marrow. For AML, it is used in combination with other medications, such as azacitidine, decitabine, or low-dose cytarabine.

Patient Eligibility

For patients with CLL or SLL, Venclexta may be used alone or in combination with other cancer treatments. For patients with AML, Venclexta is specifically indicated for newly diagnosed adults who:

• Are 75 years of age or older, or
• Have other medical conditions that prevent the use of standard, intensive induction chemotherapy.

Targeting the BCL-2 Protein

Venclexta is a type of targeted therapy known as a B-cell lymphoma-2 (BCL-2) inhibitor. BCL-2 is a protein that helps regulate whether cells live or die. In a healthy body, this protein helps keep normal cells alive, but in certain types of cancer, the body produces too much of it.

How It Affects Cancer Cells

In cancers like chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), high levels of BCL-2 prevent cancer cells from dying. This allows the cancer to grow and spread because the cells do not follow the normal cycle of cell death. Venclexta works by directly binding to the BCL-2 protein and blocking its activity.

When Venclexta blocks BCL-2, it restores the natural process of apoptosis, also known as programmed cell death. This process includes:

• Identifying cancer cells: The medication targets cells that rely on BCL-2 for survival.
• Removing the survival shield: By inhibiting the protein, the medication removes the protection that keeps the cancer cells alive.
• Triggering cell breakdown: Once the protection is gone, the cancer cells self-destruct and are cleared away by the body.

Common Side Effects

Many people taking Venclexta experience mild to moderate side effects. These may include:

• Nausea, vomiting, or diarrhea
• Constipation
• Feeling unusually tired or weak
• Cough or upper respiratory tract infections
• Muscle, bone, or joint pain
• Swelling in the hands, legs, or feet
• Headache

Serious Side Effects

Some side effects can be severe and require prompt medical evaluation.

Tumor Lysis Syndrome (TLS)

TLS is a serious condition caused by the rapid breakdown of cancer cells. It can cause kidney failure and heart rhythm problems. Seek emergency medical care if you notice:

• Confusion or seizures
• Shortness of breath
• Irregular heartbeat
• Dark or cloudy urine
• Severe nausea or vomiting

Low Blood Cell Counts

Venclexta can significantly lower the number of white blood cells, red blood cells, and platelets. This can increase the risk of:

• Infections: Fever, chills, sore throat, or other signs of illness should be reported to a doctor immediately.
• Anemia: Feeling very tired, pale skin, or shortness of breath.
• Bleeding: Unusual bruising or bleeding that is hard to stop.

Liver Problems

In some cases, this medication may affect liver function. Symptoms can include yellowing of the skin or eyes (jaundice), dark urine, or pain in the upper right side of the stomach area.

Tumor Lysis Syndrome (TLS)

Venclexta can cause a rapid breakdown of cancer cells, leading to tumor lysis syndrome. This condition can result in kidney failure, heart rhythm problems, and death. The risk is highest when starting treatment or increasing the dose. To reduce this risk, healthcare providers use a specific dosing schedule, ensure patients are well-hydrated, and perform frequent blood tests to monitor kidney function and electrolyte levels.

Low White Blood Cell Counts

Neutropenia, a significant decrease in white blood cell counts, is a common and potentially serious side effect. This condition makes it harder for the body to fight infections. Healthcare providers monitor blood counts throughout treatment and may adjust the dose or interrupt treatment if counts become too low.

Infections

Serious and sometimes fatal infections, such as pneumonia and blood infections (sepsis), have occurred during treatment. Prompt medical attention is necessary if signs of infection, such as fever or chills, develop.

Drug Interactions

Certain medications and substances, including strong CYP3A inhibitors and grapefruit products, can significantly increase the levels of Venclexta in the body. This increase can raise the risk of tumor lysis syndrome. Healthcare providers review all current medications to identify potential interactions.

Immunizations

Live vaccines should not be given before, during, or immediately after treatment. The safety of these vaccines has not been studied in patients taking Venclexta, and they may not work as intended or could cause infection.

Pregnancy and Breastfeeding

Venclexta may cause harm to a developing fetus. Effective birth control is recommended during treatment and for at least 30 days after the final dose. Because of the potential for serious adverse reactions in a nursing child, breastfeeding is not recommended during treatment.

Pregnancy

Venclexta can cause harm to a fetus if taken during pregnancy. While there are no well-controlled studies in pregnant humans, animal studies and the drug's mechanism of action suggest a risk of fetal toxicity. Healthcare providers typically require a pregnancy test before starting treatment to ensure the patient is not pregnant.

Effective birth control should be used during treatment and for at least 30 days after the final dose of Venclexta. If a pregnancy occurs while taking this medication, it is important to contact a healthcare provider immediately to discuss the potential risks to the fetus.

Breastfeeding

It is not known whether Venclexta passes into human breast milk or how it might affect a nursing infant. Because of the potential for serious adverse reactions in a breastfed child, breastfeeding is not recommended during treatment and for at least one week after the last dose.

Fertility

Based on animal studies, Venclexta may impair male fertility. The long-term effects on human fertility are not fully known. Individuals concerned about their ability to have children should discuss these risks with their healthcare team before beginning treatment.

Available Forms

Venclexta is supplied as film-coated tablets intended for oral administration. The tablets are manufactured in different colors and shapes to help distinguish between the various strengths prescribed during treatment.

Packaging Options

• Starter Packs: For patients beginning therapy, the medication is often provided in specialized blister packs. These packs are organized by week to help patients follow the required schedule for gradually increasing the dose at the start of treatment.
• Bottles: The tablets are also available in plastic bottles for ongoing maintenance therapy after the initial dose-escalation phase is complete.

FDA Approval and Indications

Venclexta received its initial FDA approval in April 2016. It is currently indicated for the treatment of adults with the following conditions:

• Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL): Approved for use as a single agent or in combination with other medications.
• Acute Myeloid Leukemia (AML): Approved for use in combination with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed patients who are 75 years or older, or who have medical conditions that prevent the use of intensive induction chemotherapy.

Regulatory Considerations

The approval for acute myeloid leukemia was granted under the FDA accelerated approval pathway. This pathway allows for the earlier approval of drugs that treat serious conditions and fill an unmet medical need based on data showing the drug has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. Continued approval for this specific use may depend on the results of confirmatory clinical trials.

There is no Risk Evaluation and Mitigation Strategy (REMS) or Boxed Warning currently required for Venclexta. However, the FDA-approved labeling includes significant warnings regarding Tumor Lysis Syndrome (TLS). Because of the risk of TLS, the FDA requires a specific five-week dose-escalation schedule and strict adherence to hydration and monitoring protocols during the initial phase of treatment.

Insurance and Out-of-Pocket Costs

The price of Venclexta is primarily influenced by health insurance coverage. Most plans, including Medicare Part D, cover the medication, but it is often classified as a specialty drug. This classification may result in higher out-of-pocket costs, such as coinsurance or deductibles, depending on the specific plan's formulary.

Specialty Pharmacy Access

Venclexta is generally dispensed through specialty pharmacies rather than standard retail pharmacies. These facilities are equipped to handle the specific storage and monitoring requirements of the drug. Patients are encouraged to verify which specialty pharmacies are within their insurance network to manage costs effectively.

Financial Assistance Programs

Various programs exist to help manage the cost of Venclexta treatment:

• Copay Savings Cards: Patients with commercial insurance may be eligible for savings cards that reduce monthly out-of-pocket expenses.
• Patient Assistance: For those without insurance or with limited coverage, manufacturer-sponsored programs may provide the medication at a reduced cost or for free to those who meet financial eligibility requirements.
• Support Organizations: Non-profit foundations may offer financial aid to help patients cover the costs of oncology medications.